A meta-path, attention-based deep learning method to support hepatitis carcinoma predictions for improved cirrhosis patient management

Hepatitis carcinoma (HCC) accounts for the majority of liver cancer–related deaths globally. Cirrhosis often precedes HCC clinically in a strong, temporal relationship. Therefore, identifying cirrhosis patients at higher risk of HCC is crucial to physicians' clinical decision-making and patient management. Effective estimates of at-risk patients can facilitate timely therapeutic interventions and thereby enhance patient outcomes and well-being. We develop a novel, meta-path, attention-based deep learning method to identify at-risk cirrhosis patients. The proposed method integrates complex patient–medication interactions, essential patient–patient and medication–medication links, and the combined effects of medication and comorbidity to support downstream predictions. An empirical test of the proposed method's predictive utilities, relative to nine existing methods, uses a large sample of real-world cirrhosis patient data. The comparative results indicate that the proposed method can identify at-risk patients more effectively than all the benchmarks. The current research has important implications for clinical decision support and patient management, and it can facilitate patient self-management and treatment compliance too.